Skip to search formSkip to main contentSkip to account menu

evolocumab

Known as: AMG 145, AMG-145 
National Institutes of Health

Related topics

Related topics

7 relations
1 ML evolocumab 140 MG/ML Auto-Injector [Repatha]1 ML evolocumab 140 MG/ML Prefilled Syringe1 ML evolocumab 140 MG/ML Prefilled Syringe [Repatha]3.5 ML evolocumab 120 MG/ML Cartridge [Repatha]

Narrower (1)

Repatha

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Realizing Value With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Are We Closer to Finding the Sweet Spot?
2018
2018
Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the…
Alkhalil acknowledges the concept of higher absolute baseline risk generally translating to greater absolute risk reductions with… 
2017
2017
Abstract 15100: Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial
Introduction: Intensive LDL-C lowering with the PCSK9i evolocumab (EvoMab) significantly reduced the risk of major vascular… 
Review
2017
Review
2017
PCSK9 inhibitors and managing cost in the managed care setting.
In patients with hypercholesterolemia who have atherosclerotic cardiovascular disease and/or familial hypercholesterolemia, a new… 
2016
2016
Access to medicines report cards
2016
2016
Health Plans and Drug Companies Dip Their Toes Into Value-Based Pricing: The Pressure Is on P&T Committees to Monitor Utilization.
The agreement between Harvard Pilgrim and Amgen on a "pay for performance" deal involving evolocumab could encourage other… 
Review
2015
Review
2015
Evolocumab (Repatha)--a second PCSK9 inhibitor to lower LDL-Cholesterol.
The second FDA-approved PCSK9 inhibitor evolocumab (Repatha) appears to be similar in efficacy and safety to alirocumab (Praluent… 
2015
2015
Evolocumab approved for reducing LDL cholesterol.
FDA and Amgen on August 27 announced the approval of evolocumab injection as add-on therapy to reduce low-density lipoprotein… 
2013
2013
Abstract 12621: Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance
Background: In the GAUSS Phase 2 12-week placebo-controlled trial in statin-intolerant patients, AMG 145, a monoclonal antibody… 
2013
2013
Abstract 12191: Efficacy and Safety of Long-Term Treatment With AMG 145 Monotherapy
Background: AMG 145, a fully human monoclonal antibody against PCSK9, was well tolerated and significantly reduced low-density… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)